PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
0.00 - 0.01
0.00 - 0.02
289 / 496.9K (Avg.)
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-76.37%
Both firms have declining sales. Martin Whitman would suspect an industry slump or new disruptive entrants.
-60.22%
Both firms have negative gross profit growth. Martin Whitman would question the sector’s viability or cyclical slump.
-82.23%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-82.23%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-81.32%
Negative net income growth while XRF.AX stands at 13.78%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-80.00%
Negative EPS growth while XRF.AX is at 12.54%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-80.00%
Negative diluted EPS growth while XRF.AX is at 12.54%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
4.62%
Share count expansion well above XRF.AX's 1.21%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
12.14%
Diluted share count expanding well above XRF.AX's 1.24%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
-54.43%
Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.
-32.83%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
-50.22%
Negative 10Y revenue/share CAGR while XRF.AX stands at 151.40%. Joel Greenblatt would question if the company is failing to keep pace with industry changes.
112.77%
5Y revenue/share CAGR above 1.5x XRF.AX's 74.52%. David Dodd would look for consistent product or market expansions fueling outperformance.
49.41%
3Y revenue/share CAGR similar to XRF.AX's 49.22%. Walter Schloss would assume both companies experience comparable short-term cycles.
4276.79%
10Y OCF/share CAGR above 1.5x XRF.AX's 132.15%. David Dodd would check if a superior product mix or cost edge drives this outperformance.
457.75%
Below 50% of XRF.AX's 1139.05%. Michael Burry would be alarmed about sustained underperformance in generating free operational cash.
259.99%
3Y OCF/share CAGR above 1.5x XRF.AX's 144.47%. David Dodd would confirm if the firm is quickly gaining an operational edge over the competitor.
121.31%
Net income/share CAGR at 50-75% of XRF.AX's 198.79%. Martin Whitman might question if the firm’s product or cost base lags behind.
2783.33%
5Y net income/share CAGR above 1.5x XRF.AX's 195.12%. David Dodd would confirm if the firm’s strategy is more effective in generating mid-term profits.
0.58%
Below 50% of XRF.AX's 72.97%. Michael Burry suspects a steep short-term disadvantage in bottom-line expansion.
No Data
No Data available this quarter, please select a different quarter.
609.64%
5Y equity/share CAGR above 1.5x XRF.AX's 52.04%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
87.12%
3Y equity/share CAGR above 1.5x XRF.AX's 30.57%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-76.11%
Both reduce receivables yoy. Martin Whitman suspects a shift in the entire niche’s credit approach or softer demand.
5.31%
Inventory growth well above XRF.AX's 4.59%. Michael Burry suspects overshooting production or weaker sell-through vs. the competitor.
1.87%
Positive asset growth while XRF.AX is shrinking. John Neff sees potential for us to outgrow the competitor if returns are solid.
-0.88%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
-13.08%
We’re deleveraging while XRF.AX stands at 35.08%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
No Data
No Data available this quarter, please select a different quarter.
-35.81%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.